Paliperidone 6-Month Im Injection Suppliers & Bulk Manufacturers
Available Forms: Once-6-Month IM Injection
Available Strengths: 1,092 mg, 1,560 mg
Reference Brands: Invega Hafyera®(US)
Category:
Antipsychotropic Drugs
Paliperidone is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, helping to reduce psychotic symptoms and stabilize mood. The 6-month intramuscular injection offers long-term treatment for schizophrenia in adults, improving adherence by reducing dosing frequency. It maintains steady plasma levels, minimizing relapse risk in stabilized patients.
Paliperidone 6-Month IM Injection is available in Once-6-Month IM Injection
and strengths such as 1,092 mg, 1,560 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Paliperidone 6-Month IM Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Paliperidone 6-Month IM Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Paliperidone 6-month intramuscular injection (brand name: Invega Hafyera) is FDA-approved in the United States for the maintenance treatment of schizophrenia in adults stabilized on 1-month or 3-month paliperidone formulations. It is designed to improve adherence and reduce relapse by offering long-term dosing. In the European Union, this 6-month version is not yet widely approved, requiring a new EMA submission via the centralized procedure. Regulatory requirements include GMP-compliant long-acting injectable technology, bridging pharmacokinetic studies, and thorough safety evaluations. U.S. labelling carries boxed warnings for elderly dementia-related psychosis. Explore sourcing options at Pharmatradz.com — your B2B pharma partner.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing